Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project-Part 2)

  • Etude concernée: ERMETIC
  • Auteurs / Authors: Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP
  • Journal / Conference: Annals of Oncology
  • Année / Year: 2012
  • PMID: 22982650
  • Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/22982650